Reglan Tardive Dyskinesia Settlement: Understanding the Statute of Limitations in Arizona

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Education to Targeted Risk Awareness

For decades, general health and science information has served as the foundation for public understanding of medication risks and patient safety. This broad educational framework has empowered individuals to recognize potential adverse effects associated with prescription drugs, particularly those used in long-term treatment regimens. Within this legacy context, the focus has remained on raising awareness about drug interactions, side effects, and the importance of informed consent in clinical settings. As this foundational knowledge evolved, attention increasingly turned to specific medications with documented long-term safety concerns. One such medication is Reglan (metoclopramide), commonly prescribed for gastrointestinal disorders. Over time, clinical experience and patient reports highlighted a significant risk: prolonged use of Reglan could lead to tardive dyskinesia, a serious movement disorder. This recognition shifted the conversation from general health education to a more targeted concern about occupational exposure. In mass production environments, workers may face unique challenges in managing medication regimens due to shift work, stress, and limited access to consistent healthcare. The transition from broad health literacy to this specific occupational exposure concern underscores the need for tailored risk communication and monitoring protocols in industrial settings.

Reglan and Tardive Dyskinesia: A Documented Risk

Reglan (metoclopramide) is a medication approved for short-term treatment of symptomatic gastroesophageal reflux in adults and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, its use carries a significant risk of tardive dyskinesia (TD), a potentially irreversible movement disorder. The FDA-approved boxed warning states that metoclopramide, including Reglan, can cause TD, and the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the label instructs prescribers to use the drug for the shortest duration necessary and to periodically reassess the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, the label advises avoiding treatment longer than 12 weeks, and if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities. The prescribing information describes TD as a syndrome of potentially irreversible and disfiguring involuntary movements (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Metoclopramide may also suppress or partially suppress the signs of TD, potentially delaying diagnosis because it can mask the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The label warns that Reglan is not recommended for use in pediatric patients due to the risk of TD and other extrapyramidal symptoms, as well as the risk of methemoglobinemia in neonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Mechanism of Action and Risk Factors

The mechanistic pathway linking Reglan to TD involves metoclopramide's action as a dopamine receptor antagonist in the central nervous system. Chronic blockade of dopamine D2 receptors in the basal ganglia is believed to lead to upregulation of these receptors and subsequent supersensitivity, which manifests as the involuntary movements characteristic of TD. The risk is dose-dependent and cumulative, with longer exposure increasing the likelihood of developing the condition. For patients in Arizona considering a settlement related to Reglan-induced TD, several factors are relevant. The statute of limitations for filing a claim in Arizona is typically two years from the date the injury was discovered or should have been discovered with reasonable diligence. This timeline is critical because TD may develop months or years after starting Reglan, and symptoms can be subtle initially. The adequacy of warnings is a key consideration: the FDA-approved label includes a boxed warning about TD, but patients may not have been adequately informed by their prescribers about the risks, especially if the medication was used off-label or for longer than recommended. The label explicitly states that Reglan has not been shown to be safe and effective for gastroesophageal reflux for longer than 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If a patient was prescribed Reglan for extended periods without proper monitoring or warning, this could support a claim that the manufacturer or prescriber failed to provide adequate risk information.

Settlement Considerations for Arizona Patients

Settlement considerations also depend on the timeline between exposure and documented harm. The boxed warning emphasizes that the risk of TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Therefore, patients who used Reglan for longer than 12 weeks, or who received high cumulative doses, are at greater risk and may have stronger claims. Additionally, the label advises immediate discontinuation of Reglan if signs or symptoms of TD develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Failure to do so could exacerbate the condition and affect the severity of harm. In summary, the evidence indicates that Reglan carries a well-documented risk of TD, with specific warnings about duration of use and cumulative dosage. For Arizona patients, the statute of limitations and the adequacy of warnings are central to any settlement claim. The clinical presentation of TD, its potential irreversibility, and the mechanistic link to metoclopramide's dopamine-blocking effects underscore the importance of timely diagnosis and legal action. Patients should consult with a medical professional and legal expert to assess their individual circumstances.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan-induced tardive dyskinesia claims in Arizona?

In Arizona, the statute of limitations for filing a claim related to Reglan-induced tardive dyskinesia is typically two years from the date the injury was discovered or should have been discovered with reasonable diligence. Because TD may develop months or years after starting Reglan, it is crucial to act promptly once symptoms are recognized.

How does the FDA label address the risk of tardive dyskinesia with Reglan?

The FDA-approved label for Reglan includes a boxed warning stating that metoclopramide can cause tardive dyskinesia, and the risk increases with duration of treatment and total cumulative dosage. The label advises using the drug for the shortest duration necessary, with a maximum of 12 weeks for gastroesophageal reflux, and recommends routine monitoring for TD if longer-term use is unavoidable (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Reglan Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.